GIP Receptor Research: Why the “Other Incretin” Matters in Metabolic Pathway Studies
GIP is often treated as the quieter partner beside GLP-1, but GIP receptor biology is central to how researchers interpret modern incretin co-agonist studies.
Research Insights
GIP Receptor Research: Why the “Other Incretin” Matters in Metabolic Pathway Studies
GIP is often treated as the quieter partner beside GLP-1, but GIP receptor biology is central to how researchers interpret modern incretin co-agonist studies.
GLP-1 gets most of the attention in metabolic peptide discussions. That makes sense. GLP-1 receptor signaling is deeply studied, widely discussed, and central to many modern incretin-based research programs.
But GLP-1 is not the whole incretin story.
GIP, short for glucose-dependent insulinotropic polypeptide, is another incretin hormone. It is released from intestinal K cells after nutrient exposure and binds the GIP receptor, a class B G protein-coupled receptor. Like GLP-1, it is involved in post-meal signaling between the gut, pancreas, adipose tissue, brain, and broader metabolic systems.
For a long time, GIP was treated as the less exciting incretin because its insulinotropic effect appears blunted in some type 2 diabetes research contexts. That older framing is now too simple. Modern dual-receptor and multi-receptor peptide studies have pushed GIP receptor biology back into the center of metabolic research.